The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to advance understanding of the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The $833,681 award to The Children's Hospital Corporation (Boston Children's Hospital) will fund research to decipher the molecular mechanisms by which targeting cardiac endothelial epsins can enhance...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Johns Hopkins University provides $1,402,988.66 in funding from September 1, 2024 to July 31, 2028. The project aims to investigate the role of protein kinase G (PKG) and the ubiquitin ligase CHIP in enhancing the degradation of mutant transthyretin to attenuate cardiac amyloidosis. Key objectives include: Testing if PKG stimulation or expression of a CHIP...
This $693,261 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Baylor College of Medicine aims to investigate the Hippo-YAP signaling pathway and its role in promoting cardiac regenerative repair following myocardial infarction. The central hypothesis is that gene therapy strategies to knock down Hippo signaling in cardiac tissue can improve cardiac function in mouse models of ischemic heart failure. Key objectives...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,245,515.38 to The Methodist Hospital Research Institute (HMRI) to investigate the role of cell metabolism and epigenetic regulation in transdifferentiation and vascular regeneration. The research aims to determine how inflammatory signaling and metabolic shifts can facilitate the transformation of fibroblasts into endothelial cells,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $361,083 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, OH. The grant supports research on how acetylation regulates the subcellular localization of the transcription factor YAP and its role in cardiac regeneration. The 5-year project aims to investigate how metabolic stresses affect YAP acetylation through the NAD+/SIRT1/2 axis, and whether...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) provides $549,796 to Cedars-Sinai Medical Center to conduct research focused on understanding how mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) can impact cardiac metabolism and lead to cardiomyopathy and heart failure. The key research objectives are to: 1) Examine alterations in heart oxidative metabolism in response to TET2 or...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $100,480 to The University of Texas Southwestern Medical Center to conduct research on understanding the roles of nuclear envelope proteins and DNA damage in cardiomyopathy. The key objectives of this 2-year research project are to: 1) characterize the DNA damage and DNA damage response in cardiomyocytes carrying LEMD2 mutations...
This $1,344,373 Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports research to investigate cardiac regeneration in human cells and zebrafish models. The primary objectives are to: (I) assess the dynamic gene regulatory networks involved in zebrafish heart regeneration using single-cell ATAC-seq, (II) interrogate the reactivation of developmental gene programs in human cardiac organoids after injury using multiomics...